[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596266":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":53,"collaborators":20,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":77,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Shanghai Tongji Hospital, Tongji University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR-T cells（ chimeric antigen receptor T cells）","EXPERIMENTAL","CT1190B-P and CT1192 cells infusion",[13],"Drug: Chimeric Antigen Receptor T Cells (CAR-T)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Chimeric Antigen Receptor T Cells (CAR-T)","chimeric antigen receptor T cells",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Aibin Liang MD,Ph.D.","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+86 21 6611 1019","lab7182@tongji.edu.cn",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Ping Li MD","+86 135 6418 1131","lilyforever@126.com",[35],{"facility":36,"status":20,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Shanghai Tongji Hospital","Shanghai","Shanghai Municipality","200065","China","CN",{"type":43,"coordinates":44},"Point",[45,46],121.45806,31.22222,{"lat":46,"lon":45},[49,51,52],{"name":50,"role":27,"phone":28,"phoneExt":20,"email":29},"Aibin Liang MD，Ph.D.",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Aibin Liang，MD，Ph.D.","Principal Investigator","100596266","phase-1-a-clinical-study-exploring-universal-car-t-cell-in-patients-with-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia-100596266",false,"NCT07043218","A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed\u002FRefractory B-cell Acute Lymphoblastic Leukemia","A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of Universal CAR-T Cell in Patients With CD19 and\u002For CD20 Positive Relapsed\u002FRefractory B-cell Acute Lymphoblastic Leukemia.","Inclusion Criteria:\n\n1. Participants must voluntarily sign the informed consent form (ICF) and must be willing and be able to adhere to the study visit schedule and other protocol requirements\n2. 18-75 years old;\n3. Histologically or cytologically confirmed B-ALL;\n4. Previously received at least 2 lines of systemic therapy;\n5. Expected survival \\> 12 weeks;\n6. Eastern Cooperative Oncology Group (ECOG) score 0-2;\n7. Female participants of childbearing potential must have a negative pregnancy test at screening and prior to receiving preconditioning therapy。Both male and Female are willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment and are absolutely prohibited from donating sperm donation or eggs for 1 year after receiving study treatment infusion during the study.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Has HIV, syphilis infection, active hepatitis B virus infection (HBsAg positive and HBV-DNA above the detection limit), or active hepatitis Cvirus infection (HCV antibody and HCV-DNA positive);\n3. Has any current uncontrolled active infection, including but not limited to participants with active tuberculosis (investigator 's judgment);\n4. Participants' toxicities caused by previous treatment did not recover to Common Terminology Criteria for Adverse Events (CTCAE) ≤ Grade1, except alopecia and other events that are judged tolerable by the investigator;\n5. Patients with isolated extramedullary lesions;\n6. Vaccination with live attenuated vaccines, inactivate vaccines or RNA vaccines within 4 weeks prior to informed consent;\n7. Participants who are allergic or intolerant to preconditioning drugs, tocilizumab, or have other previous history of severe allergy such as anaphylactic shock;\n8. Patients with heart disease in the 6 months prior to screening;\n9. Presence of a second primary malignancy requiring treatment or not in complete remission within the past 2 years;\n10. Serious pulmonary diseases that are judged by the investigator to potentially endanger the patient's life when participating in the study.","ALL","18 Years","75 Years",{"count":67,"type":68},36,"ESTIMATED","INTERVENTIONAL",[71],"PHASE1","A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT119X(including CT1190-P and CT1192) CAR-T Cell therapy, in Patients with Relapsed\u002FRefractory B-cell acute lymphoblastic leukemia.",[74],"B-cell Acute Lymphoblastic Leukemia",[76],"CT119X","NOT_YET_RECRUITING","2025-06-22",{"date":80,"type":81},"2025-06-29","ACTUAL",{"date":83,"type":68},"2025-07-10",{"date":85,"type":68},"2027-06-30",{"name":5,"class":6},1]